PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

C. Carlo-Stella; Y. Linhares; M. D. Gandhi; M. Chung; H. Adamis; D. Ungar; M. Hamadani

doi:10.1002/HON.163_2880

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

C. Carlo-Stella, Y. Linhares, M. D. Gandhi, M. Chung, H. Adamis, D. Ungar, M. Hamadani

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Hematological Oncology
Volume	39
DOIs	https://doi.org/10.1002/HON.163_2880
State	Published - Jun 17 2021

Disciplines

Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1002/HON.163_2880License: Unspecified

Cite this

@article{20356bf663df4a148d4dca940cc0f157,

title = "PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5",

author = "C. Carlo-Stella and Y. Linhares and Gandhi, {M. D.} and M. Chung and H. Adamis and D. Ungar and M. Hamadani",

note = "Introduction: Patients (pts) with diffuse large B-cell lymphoma (DLBCL) for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell transplantation (SCT) have poor outcomes with salvage therapy.",

year = "2021",

month = jun,

day = "17",

doi = "10.1002/HON.163_2880",

language = "American English",

volume = "39",

journal = "Hematological Oncology",

}

TY - JOUR

T1 - PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

AU - Carlo-Stella, C.

AU - Linhares, Y.

AU - Gandhi, M. D.

AU - Chung, M.

AU - Adamis, H.

AU - Ungar, D.

AU - Hamadani, M.

N1 - Introduction: Patients (pts) with diffuse large B-cell lymphoma (DLBCL) for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell transplantation (SCT) have poor outcomes with salvage therapy.

PY - 2021/6/17

Y1 - 2021/6/17

UR - https://onlinelibrary.wiley.com/doi/10.1002/hon.163_2880?af=R

U2 - 10.1002/HON.163_2880

DO - 10.1002/HON.163_2880

M3 - Article

VL - 39

JO - Hematological Oncology

JF - Hematological Oncology

ER -

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

Disciplines

Access to Document

Other files and links

Cite this